PMC8641632_01
the levels of inflammatory and anti-inflammatory cytokines during COVID-19 infection and after the use of Tocilizumab therapyfor patient 1 (day 0: is the day admission tohospital)
PAMJ-40-126-g001.jpg
PMC8641632_01_PAMJ-40-126-g001.jpg
F1
Biological parameters at admission showed a high level of C-reactive protein (CRP) at 224 mg/L(8 mg/ml threshold) and a lymphopenia at 900 cells/mm3 (normal range: 1000-7000 cells/mm3) and a high blood concentration level of Interleukin-6 (IL-6) at 75.6pg/ml (threshold 5 pg/ml) (Figure 1). The IL-6 concentration increased significantly to 3432pg/ml (Figure 1). IL-6 (227 pg/ml) (Figure 1). In day 13, CRP level (0 mg/ml) and lymphocytes (2020 cells /mm3) were normal and the patient was discharged at day 20.
PMC8641632_02
the levels of inflammatory and anti-inflammatory cytokines during COVID-19 infection and after the use of Tocilizumab therapy for patient 2 (day 0: is the day admission to hospital)
PAMJ-40-126-g002.jpg
PMC8641632_02_PAMJ-40-126-g002.jpg
F2
There was a high level of CRP (51 mg/l) with normal blood lymphocyte concentration (2450/mm3) and the level of IL-6 was123 pg/ml (Figure 2). There was a decrease in the level of IL-6 (60 pg/ml) (Figure 2).